Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-TUBB3/Beta Tubulin Antibody (R2E48)

Catalog #:   RHG56703 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IF, IHC, IP, WB
Accession: Q13509
Overview

Catalog No.

RHG56703

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IF: 1:50-1:200, IHC: 1:50-1:100, IP: 1:20, WB: 1:500-1:1000

Target

Tubulin beta-III, TUBB4, TUBB3, Tubulin beta-4 chain, Tubulin beta-3 chain

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q13509

Applications

IF, IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R2E48

Data Image
  • Immunofluorescence
    Immunocytochemistry analysis of beta III Tubulin (green) in Hela using beta III Tubulin antibody,and DAPI(blue).
  • Immunohistochemical
    Immunohistochemistry analysis of paraffin-embedded Human Cholangiocarcinoma using beta III Tubulin antibody. High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.
  • Western blot
    Western blot analysis of beta III Tubulin in mouse brain lysates using beta III Tubulin antibody.
  • Western blot
    Western blot analysis of beta III Tubulin in rat Brain, Hela lysates using beta III Tubulin antibody.
References

Pathophysiological mechanisms of hair follicle regeneration and potential therapeutic strategies., PMID:40518544

Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies., PMID:40518502

Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III., PMID:40518488

High mobility group protein 2 (HMGA2) is highly expressed in a broad range of benign and malignant tumors., PMID:40518465

Glioportal: a comprehensive transcriptomic resource unveiling ligand-mediated mesenchymal transition in glioblastoma., PMID:40518441

Tildrakizumab 200 mg: a step forward in psoriasis treatment with added metabolic benefits., PMID:40518438

[Analysis of inhalant and food allergen-specific IgE in a children's hosipital in Suzhou City from 2017 to 2024]., PMID:40518417

[Analysis of sensitization characteristics and changing trends of common allergens in a children's hospital in Shanghai City from 2020 to 2024]., PMID:40518416

[Analysis of the clinical efficacy and safety of dupilumab in the treatment of patients with moderate to severe atopic dermatitis complicated with asthma]., PMID:40518414

[Advances in the evaluation and prediction of the efficacy of allergen-specific immunotherapy]., PMID:40518411

Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study., PMID:40518372

Highly sensitive nanobody-immunosensor for macrophage-capping protein., PMID:40518371

Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature., PMID:40518311

[Pharmacological characteristics of tisotumab vedotin (recombinant) (TIVDAK® 40 ‍mg Intravenous Solution) and clinical study results in recurrent or metastatic cervical cancer]., PMID:40518306

Purification of Recombinant Monoclonal Antibodies from Transgenic Chicken Eggs and Removal of Egg-White Proteins., PMID:40518304

Advancing hepatobiliary diagnosis and treatment using shortwave-infrared fluorescence imaging with ICG-C9., PMID:40518281

Seroprevalence of Neospora caninum infection in cattle and yaks in the northern mountainous regions of Kyrgyzstan., PMID:40518251

Investigation of Schmallenberg virus and update on the serological status of Toxoplasma gondii in goat herds in the semiarid region of Pernambuco state, Brazil., PMID:40518245

Precision medicine approaches to CNS metastatic disease., PMID:40518193

[Clinical analysis of 4 cases of juvenile dermatomyositis complicated with massive hemorrhage of digestive tract]., PMID:40518160

Molecular chaperones: A revolutionary approach for increased solubility of recombinant mAbs from bacterial and yeast systems., PMID:40518128

Characteristics of Kawasaki disease in children with a history of COVID-19., PMID:40517900

Journal of Oral Biosciences Proteolytic N-terminal processing of Mfa proteins in the periodontal pathogen Porphyromonas gingivalis., PMID:40517809

Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads., PMID:40517671

Rapid detection of duck egg ovalbumin (D-OVA) in surimi via fluorescent immunochromatographic assay utilizing shark-derived single-domain antibody., PMID:40517652

Interlaboratory study to assess precision and reproducibility of the meningococcal antigen surface expression (MEASURE) assay to quantify factor H binding protein expression at the surface of meningococcal serogroup B strains., PMID:40517645

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial., PMID:40517603

Evolution of TROP2: Biological insights and clinical applications., PMID:40517574

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches., PMID:40517548

Multiple Myeloma Unpacked., PMID:40517540

Incident COVID-19 infections before Omicron in the U.S., PMID:40517531

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects., PMID:40517443

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation., PMID:40517442

T-Cell Redirecting Strategies in Large B-Cell Lymphoma and Follicular Lymphoma., PMID:40517438

A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma., PMID:40517417

Cas9- and Cas12a-mediated excision and replacement of the celiac disease-related α-gliadin immunogenic complex in hexaploid wheat., PMID:40517395

Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical., PMID:40517362

Assessment of Lyme Seroconversion Among US Military Personnel in Honduras., PMID:40517326

Therapeutic Effect of Galactosyltransferase- and Sialyltransferase-encoding mRNA in Rheumatoid Arthritis., PMID:40517291

Positive coactivator PC4 shows dynamic nucleolar distribution required for rDNA transcription and protein synthesis., PMID:40517275

Quantitative response assessment of combined immunotherapy in a murine melanoma model using multiparametric MRI., PMID:40517176

Doubling multiplexed imaging capability via spatial expression pattern-guided protein pairing and computational unmixing., PMID:40517167

Advances in molecular pathology and therapy of non-small cell lung cancer., PMID:40517166

Enhanced visualization of colonic polyps using a fluorophore-conjugated claudin-1 antibody in a CPC-APC mouse model., PMID:40517099

Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma., PMID:40516919

The Role of Tumor Microenvironment and Immune Cell Crosstalk in Triple-Negative Breast Cancer (TNBC): Emerging Therapeutic Opportunities., PMID:40516902

Potential blocker of SARS-CoV entry and a narrow functionality of its spike protein motifs on Qubevirus platform., PMID:40516871

Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations., PMID:40516870

A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC., PMID:40516821

Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma., PMID:40516820

Datasheet
$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-TUBB3/Beta Tubulin Antibody (R2E48) [RHG56703]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only